{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T06:15:43Z","timestamp":1773987343190,"version":"3.50.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["3546\/19"],"award-info":[{"award-number":["3546\/19"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["3546\/19"],"award-info":[{"award-number":["3546\/19"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006245","name":"Ministry of Science and Technology, Israel","doi-asserted-by":"publisher","award":["3-16841"],"award-info":[{"award-number":["3-16841"]}],"id":[{"id":"10.13039\/501100006245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006245","name":"Ministry of Science and Technology, Israel","doi-asserted-by":"publisher","award":["3-16841"],"award-info":[{"award-number":["3-16841"]}],"id":[{"id":"10.13039\/501100006245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Microb Cell Fact"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Type I interferons (IFN-I)\u2014a group of cytokines with immunomodulatory, antiproliferative, and antiviral properties\u2014are widely used as therapeutics for various cancers and viral diseases. Since IFNs are proteins, they are highly susceptible to degradation by proteases and by hydrolysis in the strong acid environment of the stomach, and they are therefore administered parenterally. In this study, we examined whether the intestinal bacterium, enteropathogenic <jats:italic>Escherichia coli<\/jats:italic> (EPEC), can be exploited for oral delivery of IFN-Is. EPEC survives the harsh conditions of the stomach and, upon reaching the small intestine, expresses a type III secretion system (T3SS) that is used to translocate effector proteins across the bacterial envelope into the eukaryotic host cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In this study, we developed an attenuated EPEC strain that cannot colonize the host but can secrete functional human IFN\u03b12 variant through the T3SS. We found that this bacteria-secreted IFN exhibited antiproliferative and antiviral activities similar to commercially available IFN.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>These findings present a potential novel approach for the oral delivery of IFN via secreting bacteria.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12934-024-02397-y","type":"journal-article","created":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T13:01:56Z","timestamp":1717246916000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Secretion of functional interferon by the type 3 secretion system of enteropathogenic Escherichia coli"],"prefix":"10.1186","volume":"23","author":[{"given":"Irina","family":"Rostovsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uri","family":"Wieler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alona","family":"Kuzmina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Taube","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neta","family":"Sal-Man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,1]]},"reference":[{"issue":"5","key":"2397_CR1","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nri1604","volume":"5","author":"LC Platanias","year":"2005","unstructured":"Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5(5):375\u201386.","journal-title":"Nat Rev Immunol"},{"issue":"15","key":"2397_CR2","doi-asserted-by":"publisher","first-page":"11602","DOI":"10.1074\/jbc.M610115200","volume":"282","author":"E Kalie","year":"2007","unstructured":"Kalie E, Jaitin DA, Abramovich R, Schreiber G. An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities. J Biol Chem. 2007;282(15):11602\u201311.","journal-title":"J Biol Chem"},{"issue":"16","key":"2397_CR3","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1128\/MCB.05251-11","volume":"31","author":"D Levin","year":"2011","unstructured":"Levin D, Harari D, Schreiber G. Stochastic receptor expression determines cell fate upon interferon treatment. Mol Cell Biol. 2011;31(16):3252\u201366.","journal-title":"Mol Cell Biol"},{"issue":"327","key":"2397_CR4","doi-asserted-by":"publisher","first-page":"ra50","DOI":"10.1126\/scisignal.2004998","volume":"7","author":"D Levin","year":"2014","unstructured":"Levin D, Schneider WM, Hoffmann HH, Yarden G, Busetto AG, Manor O, et al. Multifaceted activities of type I interferon are revealed by a receptor antagonist. Sci Signal. 2014;7(327):ra50.","journal-title":"Sci Signal."},{"issue":"4","key":"2397_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.7224\/1537-2073.2018-063","volume":"22","author":"M Filipi","year":"2020","unstructured":"Filipi M, Jack S. Interferons in the treatment of multiple sclerosis: a clinical efficacy, safety, and tolerability update. Int J MS Care. 2020;22(4):165\u201372.","journal-title":"Int J MS Care"},{"issue":"3","key":"2397_CR6","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.cell.2015.12.027","volume":"164","author":"CT Ng","year":"2016","unstructured":"Ng CT, Mendoza JL, Garcia KC, Oldstone MB. Alpha and beta type 1 interferon signaling: passage for diverse biologic outcomes. Cell. 2016;164(3):349\u201352.","journal-title":"Cell"},{"issue":"14","key":"2397_CR7","doi-asserted-by":"publisher","first-page":"8003","DOI":"10.1074\/jbc.273.14.8003","volume":"273","author":"L Runkel","year":"1998","unstructured":"Runkel L, Pfeffer L, Lewerenz M, Monneron D, Yang CH, Murti A, et al. Differences in activity between alpha and beta type I interferons explored by mutational analysis. J Biol Chem. 1998;273(14):8003\u20138.","journal-title":"J Biol Chem"},{"issue":"4","key":"2397_CR8","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.cell.2011.06.048","volume":"146","author":"C Thomas","year":"2011","unstructured":"Thomas C, Moraga I, Levin D, Krutzik PO, Podoplelova Y, Trejo A, et al. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell. 2011;146(4):621\u201332.","journal-title":"Cell"},{"issue":"1","key":"2397_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00262-004-0549-1","volume":"54","author":"P Tagliaferri","year":"2005","unstructured":"Tagliaferri P, Caraglia M, Budillon A, Marra M, Vitale G, Viscomi C, et al. New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-alpha) treatment of human cancer. Cancer Immunol Immunother. 2005;54(1):1\u201310.","journal-title":"Cancer Immunol Immunother"},{"key":"2397_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/BF03259051","volume":"3","author":"R Cirelli","year":"1995","unstructured":"Cirelli R, Tyring SK. Major therapeutic uses of interferons. Clin Immunother. 1995;3:27\u201387.","journal-title":"Clin Immunother."},{"issue":"12","key":"2397_CR11","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/nrd2422","volume":"6","author":"EC Borden","year":"2007","unstructured":"Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov. 2007;6(12):975\u201390.","journal-title":"Nat Rev Drug Discov"},{"key":"2397_CR12","volume":"2014","author":"NR Asmana","year":"2014","unstructured":"Asmana NR. Human interferon alpha-2b: a therapeutic protein for cancer treatment. Scientifica (Cairo). 2014;2014: 970315.","journal-title":"Scientifica (Cairo)"},{"issue":"1","key":"2397_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/jmv.27317","volume":"94","author":"F Sodeifian","year":"2022","unstructured":"Sodeifian F, Nikfarjam M, Kian N, Mohamed K, Rezaei N. The role of type I interferon in the treatment of COVID-19. J Med Virol. 2022;94(1):63\u201381.","journal-title":"J Med Virol"},{"key":"2397_CR14","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.3389\/fimmu.2020.01061","volume":"11","author":"Q Zhou","year":"2020","unstructured":"Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X, Wang X, et al. Interferon-alpha2b treatment for COVID-19. Front Immunol. 2020;11:1061.","journal-title":"Front Immunol"},{"issue":"6","key":"2397_CR15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11096-005-1319-7","volume":"27","author":"S Sleijfer","year":"2005","unstructured":"Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G. Side effects of interferon-alpha therapy. Pharm World Sci. 2005;27(6):423\u201331.","journal-title":"Pharm World Sci"},{"issue":"8","key":"2397_CR16","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1212\/WNL.53.8.1622","volume":"53","author":"EU Walther","year":"1999","unstructured":"Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology. 1999;53(8):1622\u20137.","journal-title":"Neurology"},{"issue":"6","key":"2397_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nrmicro.2017.20","volume":"15","author":"W Deng","year":"2017","unstructured":"Deng W, Marshall NC, Rowland JL, McCoy JM, Worrall LJ, Santos AS, et al. Assembly, structure, function and regulation of type III secretion systems. Nat Rev Microbiol. 2017;15(6):323\u201337.","journal-title":"Nat Rev Microbiol"},{"issue":"16","key":"2397_CR18","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.1128\/JB.186.16.5486-5495.2004","volume":"186","author":"X Charpentier","year":"2004","unstructured":"Charpentier X, Oswald E. Identification of the secretion and translocation domain of the enteropathogenic and enterohemorrhagic Escherichia coli effector Cif, using TEM-1 beta-lactamase as a new fluorescence-based reporter. J Bacteriol. 2004;186(16):5486\u201395.","journal-title":"J Bacteriol"},{"issue":"3","key":"2397_CR19","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1046\/j.1365-2958.2002.03214.x","volume":"46","author":"JA Crawford","year":"2002","unstructured":"Crawford JA, Kaper JB. The N-terminus of enteropathogenic Escherichia coli (EPEC) Tir mediates transport across bacterial and eukaryotic cell membranes. Mol Microbiol. 2002;46(3):855\u201368.","journal-title":"Mol Microbiol"},{"issue":"13","key":"2397_CR20","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1128\/JB.00046-10","volume":"192","author":"D Munera","year":"2010","unstructured":"Munera D, Crepin VF, Marches O, Frankel G. N-terminal type III secretion signal of enteropathogenic Escherichia coli translocator proteins. J Bacteriol. 2010;192(13):3534\u20139.","journal-title":"J Bacteriol"},{"issue":"12","key":"2397_CR21","doi-asserted-by":"publisher","first-page":"e15227","DOI":"10.1371\/journal.pone.0015227","volume":"5","author":"A Blanco-Toribio","year":"2010","unstructured":"Blanco-Toribio A, Muyldermans S, Frankel G, Fernandez LA. Direct injection of functional single-domain antibodies from E. coli into human cells. PLoS ONE. 2010;5(12):e15227.","journal-title":"PLoS ONE"},{"key":"2397_CR22","doi-asserted-by":"publisher","first-page":"1146000","DOI":"10.3389\/fcimb.2023.1146000","volume":"13","author":"DL Guzman-Herrador","year":"2023","unstructured":"Guzman-Herrador DL, Fernandez-Gomez A, Llosa M. Recruitment of heterologous substrates by bacterial secretion systems for transkingdom translocation. Front Cell Infect Microbiol. 2023;13:1146000.","journal-title":"Front Cell Infect Microbiol"},{"issue":"11","key":"2397_CR23","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1002\/bit.25656","volume":"113","author":"A Azam","year":"2016","unstructured":"Azam A, Li C, Metcalf KJ, Tullman-Ercek D. Type III secretion as a generalizable strategy for the production of full-length biopolymer-forming proteins. Biotechnol Bioeng. 2016;113(11):2313\u201320.","journal-title":"Biotechnol Bioeng"},{"issue":"11","key":"2397_CR24","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1128\/AEM.02576-07","volume":"74","author":"M Derouazi","year":"2008","unstructured":"Derouazi M, Toussaint B, Quenee L, Epaulard O, Guillaume M, Marlu R, et al. High-yield production of secreted active proteins by the Pseudomonas aeruginosa type III secretion system. Appl Environ Microbiol. 2008;74(11):3601\u20134.","journal-title":"Appl Environ Microbiol"},{"issue":"4","key":"2397_CR25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nbt1077","volume":"23","author":"K Majander","year":"2005","unstructured":"Majander K, Anton L, Antikainen J, Lang H, Brummer M, Korhonen TK, et al. Extracellular secretion of polypeptides using a modified Escherichia coli flagellar secretion apparatus. Nat Biotechnol. 2005;23(4):475\u201381.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"2397_CR26","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.resmic.2013.03.006","volume":"164","author":"B Reed","year":"2013","unstructured":"Reed B, Chen R. Biotechnological applications of bacterial protein secretion: from therapeutics to biofuel production. Res Microbiol. 2013;164(6):675\u201382.","journal-title":"Res Microbiol"},{"key":"2397_CR27","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/msb.2009.62","volume":"5","author":"DM Widmaier","year":"2009","unstructured":"Widmaier DM, Tullman-Ercek D, Mirsky EA, Hill R, Govindarajan S, Minshull J, et al. Engineering the Salmonella type III secretion system to export spider silk monomers. Mol Syst Biol. 2009;5:309.","journal-title":"Mol Syst Biol"},{"issue":"7","key":"2397_CR28","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1128\/JB.02401-14","volume":"197","author":"W Deng","year":"2015","unstructured":"Deng W, Yu HB, Li Y, Finlay BB. SepD\/SepL-dependent secretion signals of the type III secretion system translocator proteins in enteropathogenic Escherichia coli. J Bacteriol. 2015;197(7):1263\u201375.","journal-title":"J Bacteriol"},{"issue":"4","key":"2397_CR29","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1128\/IAI.73.4.2135-2146.2005","volume":"73","author":"W Deng","year":"2005","unstructured":"Deng W, Li Y, Hardwidge PR, Frey EA, Pfuetzner RA, Lee S, et al. Regulation of type III secretion hierarchy of translocators and effectors in attaching and effacing bacterial pathogens. Infect Immun. 2005;73(4):2135\u201346.","journal-title":"Infect Immun"},{"issue":"23","key":"2397_CR30","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.15252\/embj.201797515","volume":"36","author":"AG Portaliou","year":"2017","unstructured":"Portaliou AG, Tsolis KC, Loos MS, Balabanidou V, Rayo J, Tsirigotaki A, et al. Hierarchical protein targeting and secretion is controlled by an affinity switch in the type III secretion system of enteropathogenic Escherichia coli. EMBO J. 2017;36(23):3517\u201331.","journal-title":"EMBO J"},{"issue":"10","key":"2397_CR31","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1073\/pnas.0400326101","volume":"101","author":"W Deng","year":"2004","unstructured":"Deng W, Puente JL, Gruenheid S, Li Y, Vallance BA, Vazquez A, et al. Dissecting virulence: systematic and functional analyses of a pathogenicity island. Proc Natl Acad Sci USA. 2004;101(10):3597\u2013602.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2397_CR32","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1128\/JB.01238-08","volume":"191","author":"A Iguchi","year":"2009","unstructured":"Iguchi A, Thomson NR, Ogura Y, Saunders D, Ooka T, Henderson IR, et al. Complete genome sequence and comparative genome analysis of enteropathogenic Escherichia coli O127:H6 strain E2348\/69. J Bacteriol. 2009;191(1):347\u201354.","journal-title":"J Bacteriol"},{"issue":"6","key":"2397_CR33","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1128\/IAI.71.6.3310-3319.2003","volume":"71","author":"A Gauthier","year":"2003","unstructured":"Gauthier A, Puente JL, Finlay BB. Secretin of the enteropathogenic Escherichia coli type III secretion system requires components of the type III apparatus for assembly and localization. Infect Immun. 2003;71(6):3310\u20139.","journal-title":"Infect Immun"},{"issue":"5867","key":"2397_CR34","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1126\/science.1151721","volume":"319","author":"DG Gibson","year":"2008","unstructured":"Gibson DG, Benders GA, Andrews-Pfannkoch C, Denisova EA, Baden-Tillson H, Zaveri J, et al. Complete chemical synthesis, assembly, and cloning of a Mycoplasma genitalium genome. Science. 2008;319(5867):1215\u201320.","journal-title":"Science"},{"issue":"5","key":"2397_CR35","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nmeth.1318","volume":"6","author":"DG Gibson","year":"2009","unstructured":"Gibson DG, Young L, Chuang RY, Venter JC, Hutchison CA 3rd, Smith HO. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods. 2009;6(5):343\u20135.","journal-title":"Nat Methods"},{"issue":"1","key":"2397_CR36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/mBio.01733-16","volume":"8","author":"L Shaulov","year":"2017","unstructured":"Shaulov L, Gershberg J, Deng W, Finlay BB, Sal-Man N. The ruler protein EscP of the enteropathogenic Escherichia coli type III secretion system is involved in calcium sensing and secretion hierarchy regulation by interacting with the gatekeeper protein SepL. MBio. 2017;8(1):10.","journal-title":"MBio"},{"issue":"4","key":"2397_CR37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/mSphere.00162-18","volume":"3","author":"I Tseytin","year":"2018","unstructured":"Tseytin I, Madar A, Mitrovic B, Deng W, Finlay BB, Sal-Man N. The third transmembrane domain of EscR is critical for function of the enteropathogenic Escherichia coli type III secretion system. mSphere. 2018;3(4):10.","journal-title":"mSphere."},{"key":"2397_CR38","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.3389\/fmicb.2019.02551","volume":"10","author":"I Tseytin","year":"2019","unstructured":"Tseytin I, Mitrovic B, David N, Langenfeld K, Zarivach R, Diepold A, et al. The role of the small export apparatus protein, SctS, in the activity of the type III secretion system. Front Microbiol. 2019;10:2551.","journal-title":"Front Microbiol"},{"issue":"9","key":"2397_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/29.9.e45","volume":"29","author":"MW Pfaffl","year":"2001","unstructured":"Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9): e45.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"2397_CR40","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jmb.2005.08.042","volume":"353","author":"LC Roisman","year":"2005","unstructured":"Roisman LC, Jaitin DA, Baker DP, Schreiber G. Mutational analysis of the IFNAR1 binding site on IFNalpha2 reveals the architecture of a weak ligand-receptor binding-site. J Mol Biol. 2005;353(2):271\u201381.","journal-title":"J Mol Biol"},{"key":"2397_CR41","doi-asserted-by":"publisher","first-page":"pdb.prot095505","DOI":"10.1101\/pdb.prot095505","volume":"6","author":"P Kumar","year":"2018","unstructured":"Kumar P, Nagarajan A, Uchil PD. Analysis of cell viability by the MTT assay. Cold Spring Harb Protoc. 2018;6:pdb.prot095505.","journal-title":"Cold Spring Harb Protoc"},{"issue":"9","key":"2397_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008834","volume":"16","author":"S Krasnopolsky","year":"2020","unstructured":"Krasnopolsky S, Kuzmina A, Taube R. Genome-wide CRISPR knockout screen identifies ZNF304 as a silencer of HIV transcription that promotes viral latency. PLoS Pathog. 2020;16(9): e1008834.","journal-title":"PLoS Pathog"},{"issue":"1","key":"2397_CR43","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/emboj.2010.297","volume":"30","author":"K Baruch","year":"2011","unstructured":"Baruch K, Gur-Arie L, Nadler C, Koby S, Yerushalmi G, Ben-Neriah Y, et al. Metalloprotease type III effectors that specifically cleave JNK and NF-kappaB. EMBO J. 2011;30(1):221\u201331.","journal-title":"EMBO J"},{"key":"2397_CR44","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3389\/fimmu.2020.00542","volume":"11","author":"AC Buzzai","year":"2020","unstructured":"Buzzai AC, Wagner T, Audsley KM, Newnes HV, Barrett LW, Barnes S, et al. Diverse anti-tumor immune potential driven by individual IFNalpha subtypes. Front Immunol. 2020;11:542.","journal-title":"Front Immunol"},{"issue":"2","key":"2397_CR45","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3390\/cancers13020196","volume":"13","author":"S Gessani","year":"2021","unstructured":"Gessani S, Belardelli F. Type I interferons as joint regulators of tumor growth and obesity. Cancers (Basel). 2021;13(2):196.","journal-title":"Cancers (Basel)."},{"issue":"3","key":"2397_CR46","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1089\/jir.1984.4.375","volume":"4","author":"I Gresser","year":"1984","unstructured":"Gresser I, Maury C, Bandu MT, Foiret D, Trojan J, Uriel J. Inhibitory effect of mouse interferon on the growth of an embryonal carcinoma in mice. J Interferon Res. 1984;4(3):375\u201381.","journal-title":"J Interferon Res"},{"issue":"9","key":"2397_CR47","first-page":"856","volume":"10","author":"M Musella","year":"2021","unstructured":"Musella M, Galassi C, Manduca N, Sistigu A. The Yin and Yang of type I IFNs in cancer promotion and immune activation. Biology (Basel). 2021;10(9):856.","journal-title":"Biology (Basel)."},{"issue":"5","key":"2397_CR48","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1314424","volume":"6","author":"M Musella","year":"2017","unstructured":"Musella M, Manic G, De Maria R, Vitale I, Sistigu A. Type-I-interferons in infection and cancer: unanticipated dynamics with therapeutic implications. Oncoimmunology. 2017;6(5): e1314424.","journal-title":"Oncoimmunology"},{"key":"2397_CR49","doi-asserted-by":"publisher","first-page":"D479","DOI":"10.2741\/Sangfelt","volume":"5","author":"O Sangfelt","year":"2000","unstructured":"Sangfelt O, Erickson S, Grander D. Mechanisms of interferon-induced cell cycle arrest. Front Biosci. 2000;5:D479\u201387.","journal-title":"Front Biosci"},{"issue":"11","key":"2397_CR50","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.3390\/ijms17111832","volume":"17","author":"WY Shi","year":"2016","unstructured":"Shi WY, Cao C, Liu L. Interferon alpha induces the apoptosis of cervical cancer HeLa cells by activating both the intrinsic mitochondrial pathway and endoplasmic reticulum stress-induced pathway. Int J Mol Sci. 2016;17(11):1832.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2397_CR51","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/sj.onc.1205179","volume":"21","author":"L Thyrell","year":"2002","unstructured":"Thyrell L, Erickson S, Zhivotovsky B, Pokrovskaja K, Sangfelt O, Castro J, et al. Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene. 2002;21(8):1251\u201362.","journal-title":"Oncogene"},{"issue":"5","key":"2397_CR52","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1128\/JVI.02553-12","volume":"87","author":"S Cordeil","year":"2013","unstructured":"Cordeil S, Nguyen XN, Berger G, Durand S, Ainouze M, Cimarelli A. Evidence for a different susceptibility of primate lentiviruses to type I interferons. J Virol. 2013;87(5):2587\u201396.","journal-title":"J Virol"},{"issue":"17","key":"2397_CR53","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1128\/MCB.01808-08","volume":"29","author":"I Moraga","year":"2009","unstructured":"Moraga I, Harari D, Schreiber G, Uze G, Pellegrini S. Receptor density is key to the alpha2\/beta interferon differential activities. Mol Cell Biol. 2009;29(17):4778\u201387.","journal-title":"Mol Cell Biol"},{"issue":"12","key":"2397_CR54","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1111\/j.1462-5822.2005.00625.x","volume":"7","author":"R Mundy","year":"2005","unstructured":"Mundy R, MacDonald TT, Dougan G, Frankel G, Wiles S. Citrobacter rodentium of mice and man. Cell Microbiol. 2005;7(12):1697\u2013706.","journal-title":"Cell Microbiol"},{"issue":"4","key":"2397_CR55","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41573-019-0053-0","volume":"19","author":"DJ Drucker","year":"2020","unstructured":"Drucker DJ. Advances in oral peptide therapeutics. Nat Rev Drug Discov. 2020;19(4):277\u201389.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"2397_CR56","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3390\/pharmaceutics13040587","volume":"13","author":"AT Iacob","year":"2021","unstructured":"Iacob AT, Lupascu FG, Apotrosoaei M, Vasincu IM, Tauser RG, Lupascu D, et al. Recent biomedical approaches for chitosan based materials as drug delivery nanocarriers. Pharmaceutics. 2021;13(4):587.","journal-title":"Pharmaceutics"},{"key":"2397_CR57","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.biomaterials.2017.04.036","volume":"134","author":"L Yin","year":"2017","unstructured":"Yin L, Yuvienco C, Montclare JK. Protein based therapeutic delivery agents: contemporary developments and challenges. Biomaterials. 2017;134:91\u2013116.","journal-title":"Biomaterials"},{"issue":"4","key":"2397_CR58","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.chom.2023.03.007","volume":"31","author":"JP Lynch","year":"2023","unstructured":"Lynch JP, Gonzalez-Prieto C, Reeves AZ, Bae S, Powale U, Godbole NP, et al. Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut. Cell Host Microbe. 2023;31(4):634-49 e8.","journal-title":"Cell Host Microbe"},{"issue":"5","key":"2397_CR59","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3390\/microorganisms8050777","volume":"8","author":"HA Pendergrass","year":"2020","unstructured":"Pendergrass HA, May AE. Delivery of heterologous proteins, enzymes, and antigens via the bacterial type III secretion system. Microorganisms. 2020;8(5):777.","journal-title":"Microorganisms."},{"issue":"5376","key":"2397_CR60","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1126\/science.281.5376.565","volume":"281","author":"H Russmann","year":"1998","unstructured":"Russmann H, Shams H, Poblete F, Fu Y, Galan JE, Donis RO. Delivery of epitopes by the Salmonella type III secretion system for vaccine development. Science. 1998;281(5376):565\u20138.","journal-title":"Science"},{"issue":"2","key":"2397_CR61","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/0264-410X(95)93127-U","volume":"13","author":"NK Verma","year":"1995","unstructured":"Verma NK, Ziegler HK, Wilson M, Khan M, Safley S, Stocker BA, et al. Delivery of class I and class II MHC-restricted T-cell epitopes of listeriolysin of Listeria monocytogenes by attenuated Salmonella. Vaccine. 1995;13(2):142\u201350.","journal-title":"Vaccine"},{"issue":"1","key":"2397_CR62","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ijmm.2011.09.012","volume":"302","author":"A Wieser","year":"2012","unstructured":"Wieser A, Magistro G, Norenberg D, Hoffmann C, Schubert S. First multi-epitope subunit vaccine against extraintestinal pathogenic Escherichia coli delivered by a bacterial type-3 secretion system (T3SS). Int J Med Microbiol. 2012;302(1):10\u20138.","journal-title":"Int J Med Microbiol"},{"issue":"1","key":"2397_CR63","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12934-016-0606-4","volume":"15","author":"KJ Metcalf","year":"2016","unstructured":"Metcalf KJ, Bevington JL, Rosales SL, Burdette LA, Valdivia E, Tullman-Ercek D. Proteins adopt functionally active conformations after type III secretion. Microb Cell Fact. 2016;15(1):213.","journal-title":"Microb Cell Fact"},{"key":"2397_CR64","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3389\/fbioe.2020.00840","volume":"8","author":"D Lim","year":"2020","unstructured":"Lim D, Jung WC, Jeong JH, Song M. Targeted delivery of the mitochondrial target domain of noxa to tumor tissue via synthetic secretion system in E. coli. Front Bioeng Biotechnol. 2020;8:840.","journal-title":"Front Bioeng Biotechnol."},{"issue":"3","key":"2397_CR65","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1134\/S0006297918030069","volume":"83","author":"AA Tyurin","year":"2018","unstructured":"Tyurin AA, Kabardaeva KV, Mustafaev ON, Pavlenko OS, Sadovskaya NS, Fadeev VS, et al. Expression of soluble active interferon alphaA in Escherichia coli periplasm by fusion with thermostable lichenase using the domain insertion approach. Biochemistry (Mosc). 2018;83(3):259\u201369.","journal-title":"Biochemistry (Mosc)"},{"issue":"3","key":"2397_CR66","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221\u201334.","journal-title":"N Engl J Med"},{"issue":"4","key":"2397_CR67","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","volume":"50","author":"HM Lazear","year":"2019","unstructured":"Lazear HM, Schoggins JW, Diamond MS. Shared and distinct functions of type I and type III interferons. Immunity. 2019;50(4):907\u201323.","journal-title":"Immunity"},{"key":"2397_CR68","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3389\/fimmu.2017.00621","volume":"8","author":"S Phillips","year":"2017","unstructured":"Phillips S, Mistry S, Riva A, Cooksley H, Hadzhiolova-Lebeau T, Plavova S, et al. Peg-interferon lambda treatment induces robust innate and adaptive immunity in chronic Hepatitis B patients. Front Immunol. 2017;8:621.","journal-title":"Front Immunol"},{"issue":"10","key":"2397_CR69","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1021\/acs.biomac.7b00959","volume":"18","author":"C Canepa","year":"2017","unstructured":"Canepa C, Imperiale JC, Berini CA, Lewicki M, Sosnik A, Biglione MM. Development of a drug delivery system based on chitosan nanoparticles for oral administration of interferon-alpha. Biomacromol. 2017;18(10):3302\u20139.","journal-title":"Biomacromol"},{"issue":"5","key":"2397_CR70","doi-asserted-by":"publisher","first-page":"390","DOI":"10.2165\/00003088-199019050-00003","volume":"19","author":"RJ Wills","year":"1990","unstructured":"Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet. 1990;19(5):390\u20139.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"2397_CR71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004782","volume":"11","author":"T Mahlakoiv","year":"2015","unstructured":"Mahlakoiv T, Hernandez P, Gronke K, Diefenbach A, Staeheli P. Leukocyte-derived IFN-alpha\/beta and epithelial IFN-lambda constitute a compartmentalized mucosal defense system that restricts enteric virus infections. PLoS Pathog. 2015;11(4): e1004782.","journal-title":"PLoS Pathog"},{"issue":"1","key":"2397_CR72","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1038\/s41467-021-22928-0","volume":"12","author":"C McElrath","year":"2021","unstructured":"McElrath C, Espinosa V, Lin JD, Peng J, Sridhar R, Dutta O, et al. Critical role of interferons in gastrointestinal injury repair. Nat Commun. 2021;12(1):2624.","journal-title":"Nat Commun"},{"key":"2397_CR73","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.coviro.2015.11.005","volume":"16","author":"AN Roth","year":"2016","unstructured":"Roth AN, Karst SM. Norovirus mechanisms of immune antagonism. Curr Opin Virol. 2016;16:24\u201330.","journal-title":"Curr Opin Virol"},{"issue":"12","key":"2397_CR74","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.3390\/pathogens10121641","volume":"10","author":"M Tan","year":"2021","unstructured":"Tan M. Norovirus vaccines: current clinical development and challenges. Pathogens. 2021;10(12):1641.","journal-title":"Pathogens"},{"issue":"1","key":"2397_CR75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084259","volume":"9","author":"D Harari","year":"2014","unstructured":"Harari D, Abramovich R, Zozulya A, Smith P, Pouly S, Koster M, et al. Bridging the species divide: transgenic mice humanized for type-I interferon response. PLoS ONE. 2014;9(1): e84259.","journal-title":"PLoS ONE"},{"issue":"11","key":"2397_CR76","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1128\/iai.61.11.4654-4661.1993","volume":"61","author":"DB Schauer","year":"1993","unstructured":"Schauer DB, Falkow S. The eae gene of Citrobacter freundii biotype 4280 is necessary for colonization in transmissible murine colonic hyperplasia. Infect Immun. 1993;61(11):4654\u201361.","journal-title":"Infect Immun"}],"container-title":["Microbial Cell Factories"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12934-024-02397-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12934-024-02397-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12934-024-02397-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T14:04:12Z","timestamp":1717250652000},"score":1,"resource":{"primary":{"URL":"https:\/\/microbialcellfactories.biomedcentral.com\/articles\/10.1186\/s12934-024-02397-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2397"],"URL":"https:\/\/doi.org\/10.1186\/s12934-024-02397-y","relation":{},"ISSN":["1475-2859"],"issn-type":[{"value":"1475-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,1]]},"assertion":[{"value":"12 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Authors have no competing interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"163"}}